eFFECTOR Therapeutics (OTCMKTS:EFTR – Get Free Report) is anticipated to post its resultson Tuesday, November 17th. Analysts expect the company to announce earnings of ($6.3960) per share and revenue of $0.10 million for the quarter.
eFFECTOR Therapeutics Price Performance
EFTR opened at $0.00 on Tuesday. eFFECTOR Therapeutics has a one year low of $0.00 and a one year high of $0.02.
About eFFECTOR Therapeutics
eFFECTOR Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that regulate protein production within cancer cells. Its approach, known as translation control, is designed to interfere with the mechanisms cancer cells use to produce proteins needed for growth, survival and resistance to treatment.
The company’s investigational pipeline has included zotatifin (eFT226), an inhibitor of the eukaryotic initiation factor 4A (eIF4A), and tomivosertib (eFT508), an inhibitor of mitogen-activated protein kinase-interacting kinases 1 and 2 (MNK1/2).
Read More
- Five stocks we like better than eFFECTOR Therapeutics
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for eFFECTOR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for eFFECTOR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
